Metabolic Interaction of the Active Constituents of Coptis chinensis in Human Liver Microsomes

Songcan Liu, Xinfeng Zhang, Furong Qiu, Ping Miao, Shujiao Shen, Leilei Zhu, Jin Zeng, and Jian Jiang

Department of Clinical Pharmacology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China

Correspondence should be addressed to Furong Qiu; furong.qiu@126.com and Jian Jiang; jiangjiansg@126.com

Received 7 September 2014; Revised 24 November 2014; Accepted 24 December 2014

Academic Editor: Yuping Tang

Copyright © 2015 Songcan Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Coptis chinensis is commonly used in traditional Chinese medicine. The study investigated metabolic interaction of the active constituents (berberine, coptisine, palmatine, and jatrorrhizine) of Coptis chinensis in human liver microsomes. After incubation of the four constituents of Coptis chinensis in HLMs, the metabolism of the four constituents was observed by HPLC. The in vitro inhibition experiment between the active constituents was conducted, and IC_{50} value was estimated. Coptisine exhibited inhibitions against the formation of the two metabolites of berberine with IC_{50} values of 6.5 and 8.3 μM, respectively. Palmatine and jatrorrhizine showed the weaker inhibitory effect on the formation of the metabolites of berberine. Berberine showed a weak inhibitory effect on the production of coptisine metabolite with an IC_{50} value of 115 μM, and palmatine and jatrorrhizine had little inhibitory effect on the formation of coptisine metabolite. Berberine, coptisine, and jatrorrhizine showed no inhibitory effect on the generation of palmatine metabolite (IC_{50} > 200 μM). The findings suggested that there are different degrees of metabolic interaction between the four components. Coptisine showed the strongest inhibition toward berberine metabolism.

1. Introduction

Huanglian (Coptis chinensis), the rhizome of Coptis chinensis Franch from the Ranunculaceae family [1], has been used for hundreds of years in China and other oriental countries. The major active constituents of Coptis chinensis are isoquinoline alkaloids, including berberine, coptisine, palmatine, and jatrorrhizine [2]. The isoquinoline alkaloids are responsible for its various pharmacological effects, such as antibacterial [3], blood glucose-lowering [4] and lipid-lowering [5] effects. Coptis chinensis is widely used either alone or in combination with other herbs for patients with gastroenteritis, diabetes, and hyperlipidemia.

Some reported that berberine was metabolized mainly by CYP2D6 in HLMs [6, 7]. The metabolites of jatrorrhizine [8] have been analyzed in liver microsomes of rat. Demethylation of jatrorrhizine has been shown to be catalyzed by CYP3A1/2 and CYP2D2 in RLMs [9]. Furthermore, the constituents of Coptis chinensis have also the ability to inhibit CYP activities [10]. Some studies suggested that the availability of berberine appeared extremely low after oral administration of berberine in human and rats [11, 12]. Our previous study suggested that the AUC and C_{max} of berberine increased significantly in rats receiving Coptis chinensis extract comparing with those receiving the pure berberine (data not shown). So, it was assumed that the coexisting constituents in Coptis chinensis could enhance the oral absorption and bioavailability of berberine via metabolic interaction among these constituents of Coptis chinensis. However, metabolic interaction of the herbal constituents of Rhizoma Coptidis alkaloid in human liver microsomes has not been reported.

The objective of the present work was to investigate metabolic interaction of these active constituents (berberine, coptisine, palmatine, and jatrorrhizine) of Coptis chinensis in HLMs and to exploit metabolism-based mechanism of enhancing the oral absorption and bioavailability of the active constituents of Coptis chinensis.
2. Materials and Methods

2.1. Chemicals and Reagents. Berberine hydrochloride, coptisine hydrochloride, palmatine hydrochloride, and jatrorrhizine hydrochloride were purchased from the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China). β-Nicotinamide adenine dinucleotide phosphate reduced tetrasodium salt (NADPH) was purchased from Sigma-Aldrich Co. (St. Louis, MO, USA). HPLC-grade methanol and acetonitrile were obtained from Tedia Company Inc. (USA). Phosphate-buffered saline (PBS, 0.1 M) was supplied by Gibco Laboratories (MD, USA). Deionized water was purified using a Milli-Q system (Millipore Corporation, USA). Deionized water was purified using a Milli-Q system (Millipore Corporation, USA). Dimethyl sulfoxide (DMSO), ammonium acetate, and other chemicals were all of analytical grade and were supplied by Sinopharm Chemical Reagent Co. Ltd. (Beijing, China).

2.2. Preparation of Standard and Stock Solutions. Berberine, coptisine, palmatine, and jatrorrhizine were dissolved in 100% DMSO, acetonitrile, and methanol concentration in the incubation mixture was 0.05% v/v. The final DMSO, acetonitrile, and methanol concentration in 100 times with PBS before adding to the incubation mixture. The final DMSO, acetonitrile, and methanol concentration in the incubation mixture was 0.05% v/v.

2.3. Human Liver Microsomes. HLMs used in this study were provided by the Research Institute for Liver Diseases Co. Ltd. (Shanghai, China) and stored at −80°C until use. The microsomes were prepared from ten Mongolian individual human donor livers.

2.4. Incubation Procedure [13, 14]. A typical incubation mixture was prepared in a total volume of 200 µL as follows: 40 µL HLMs (1 mg/mL), 20 µL NADPH (10 mM), 100 µL substrate and/or 10 µL inhibitor, and 130 or 120 µL PBS (0.1 M, pH 7.4). There was a 5 min preincubation period at 37°C before the reaction was initiated by the addition of NADPH. The reaction then proceeded for 30 min at 37°C in a shaking water bath.

Controls without NADPH and without HLMs were performed to ensure that the formation of metabolites was dependent on HLMs and NADPH.

2.5. Enzyme Kinetics Analysis. Berberine, coptisine, or palmatine as the substrate (final concentrations ranging from 2.5 to 200 µM) was incubated in the mixture with HLMs and NADPH at 37°C for 30 min. The $K_m$ and $V_{max}$ values were determined by nonlinear regression analysis using the Michaelis-Menten equation: $V = \frac{V_{max} \times [S]}{(K_m + [S])}$, where $V_{max}$ is the maximal velocity of formation, [S] is the concentration of the substrate, and $K_m$ is the substrate concentration at half-maximal velocity.

2.6. Interaction between One Constituent and Other Constituents of Coptis chinensis in HLMs. When one of the three constituents (berberine, coptisine, or palmatine) was used as a substrate, the other two constituents and jatrorrhizine were used as inhibitors. The final concentration of the constituent of Coptis chinensis as a substrate was 10 µM, and the final concentration range of the Coptis chinensis constituents as inhibitors was from 0.5 to 200 µM. These inhibitors and substrates were preincubated in the presence of HLMs at 37°C for 5 min. NADPH was then added and the reaction mixture was incubated another 30 min.

2.7. Sample Preparation and HPLC Analysis. The reactions were terminated by the addition of ice-cold acetonitrile (200 µL), followed by vortexing for 3 min and centrifugation at 20,000 rpm for 10 min at 4°C to remove the denatured proteins. The supernatant (20 µL) was injected into the HPLC (Agilent, Germany) system. An Agilent series 1200 HPLC system was equipped with degasser, quaternary pump, autosampler, and UV detector. Chromatographic separation was achieved on an Agilent Eclipse XDB-C18 (4.6 mm × 150 mm, 5 µm) with mobile phase of 20 mM ammonium acetate and 0.1% formic acid in water (A)-methanol (B) at a flow rate of 1.0 mL/min. The gradient program was used as follows: 0–5 min, 20%B; 5–15 min, 20%B–35%B; 15–25 min, 35%B–45%; and 25–30 min, 20%B. The column temperature was maintained at 40°C. The peaks were determined using a UV detector set at a wavelength of 354 nm.

2.8. Data Analysis. All results are expressed as the mean ± standard deviation (SD) of the estimates obtained from the three different HLMs experiments performed in triplicate. The relative amounts of berberine, palmatine, and coptisine metabolites were expressed as the peak area of the metabolites formed. The percent inhibition was calculated from the ratio of the amount of metabolites formed with and without the specific inhibitor, and the 50% inhibitory concentration ($IC_{50}$) values and enzyme kinetic parameters $K_m$ and $V_{max}$ were calculated using GraphPad Prism 5.04 (GraphPad Prism, Inc., San Diego, CA, USA). The intrinsic clearance ($Cl_{int}$) is evaluated according to $Cl_{int} = \frac{V_{max}}{K_m}$.

3. Results

3.1. Identification of Metabolites of Berberine, Coptisine, and Palmatine with HLMs. When berberine, coptisine, palmatine, or jatrorrhizine was incubated with HLMs and NADPH for 30 min, two metabolites, one metabolite, and one metabolite of berberine, coptisine, and palmatine were, respectively, observed by HPLC, but no metabolite was observed for jatrorrhizine (Figure 1).

3.2. Enzymatic Kinetic Parameters for Berberine, Coptisine, and Palmatine Metabolites in HLMs. The $K_m$ values for the metabolites of berberine, coptisine, and palmatine in the presence of HLMs were 32.24, 32.83, 36.35, and 87.47 µM, respectively (Table 1). The $V_{max}$ values for the metabolites of berberine, coptisine, and palmatine in HLMs were 4.474, 3.371, 1.808, and 3.147 Area/min/mg protein, respectively (Table 1). The $Cl_{int}$ values for the metabolites of berberine, coptisine, and palmatine were 0.13, 0.10, 0.05, and 0.03 mAU/mg pro/µM, respectively (Table 1).
Figure 1: HPLC chromatograms of berberine, coptisine, palmatine, jatrorrhizine, and their metabolites in HLMs. Two metabolites (B1, B2) and berberine were eluted at 16.79, 18.94, and 21.20 min, respectively (a). Metabolite (C) and coptisine were eluted at 12.83 and 17.68 min, respectively (b). Metabolite (P) and palmatine were eluted at 21.66 and 19.3 min, respectively (c). Jatrorrhizine was eluted at 19.33 min (d). (1) Incubation with NADPH in HLMs, (2) no incubation with NADPH in HLMs, and (3) incubation with HLMs without NADPH.

Table 1: Enzymatic kinetic parameters for berberine, coptisine, and palmatine metabolites in HLMs.

| Metabolites | \(K_m\) (\(\mu M\)) | \(V_{max}\) (Area/min/mg/pro) | \(CL_{int}\) (Area/min/mg/pro/\(\mu M\)) |
|-------------|----------------|-------------------------------|-----------------------------------|
| B1          | 32.24          | 4.174                         | 0.13                              |
| B2          | 32.83          | 3.071                         | 0.10                              |
| C           | 36.35          | 1.808                         | 0.05                              |
| P           | 87.47          | 2.447                         | 0.03                              |

Note: B1, metabolite 1 of berberine; B2, metabolite 2 of berberine; C, metabolite of coptisine; P, metabolite of palmatine.

3.3. Interaction between One Constituent and Other Constituents of Coptis chinensis in HLMs. In HLMs, coptisine decreased the formation of the two metabolites (B1 and B2) of berberine to a similar extent with IC\(_{50}\) values of 6.5 and 8.3 \(\mu M\), respectively. The generation of metabolites (B1 and B2) of berberine was slightly inhibited by palmatine with IC\(_{50}\) values of 185 and 78.5 \(\mu M\), respectively. The production of metabolites (B2) was inhibited by jatrorrhizine with an IC\(_{50}\) value of 28.5 \(\mu M\), whereas jatrorrhizine had little inhibitory effect on the formation of B1 (IC\(_{50}\) > 200 \(\mu M\)) (Table 2).

Berberine showed an inhibitory effect on the production of coptisine metabolite with an IC\(_{50}\) value of 115 \(\mu M\). In addition, palmatine and jatrorrhizine had little inhibitory effect on the formation of coptisine metabolite (IC\(_{50}\) > 200 \(\mu M\)) (Table 2).

In the presence of HLMs, berberine, coptisine, and jatrorrhizine showed no inhibitory effect on the generation of palmatine metabolite (IC\(_{50}\) > 200 \(\mu M\)) (Table 2).

Table 2: The IC\(_{50}\) values for interaction between one constituent and other constituents of Coptis chinensis in HLMs (\(\mu M\)).

| Metabolites | Ber | COP | Pal | Jat |
|-------------|-----|-----|-----|-----|
| B1          | —   | 6.5 | 185 | >200|
| B2          | —   | 8.3 | 78.5| 28.5|
| C           | 115 | —   | >200| >200|
| P           | >200| >200| —   | >200|
4. Discussion

This is investigation of metabolic interaction of the active constituents of Coptis chinensis (berberine, coptisine, palmatine, and jatrorrhizine) in human liver microsomes for the first time. In this study, two metabolites, one metabolite of berberine, coptisine, and palmatine were observed by HPLC but no metabolite of jatrorrhizine was observed after incubation of the four constituents of Coptis chinensis in HLMs with NADPH. LC-MS/MS was used as a guide to identify these metabolites. B1 corresponded to an \([M]^+\) ion at m/z 324, which was 12 Da less than that of berberine, suggesting that B1 was a demethylated ring-opened product of berberine. B2 had an \([M]^+\) ion at m/z 322, which was a loss of 14 Da (CH₂) compared with berberine, and the metabolite (C) of coptisine had an \([M]^+\) ion at m/z 308, which was 14 Da (CH₂) lower than that for coptisine, and the metabolite (P) of palmatine had an \([M]^+\) ion at m/z 338, which was 14 Da (CH₂) lower than that of palmatine. These findings were consistent with the results of some reports [15–17] and suggested that berberine, coptisine, and palmatine could produce certain amount of phase I metabolites in HLM via oxidative demethylation.

Using recombinant human CYP enzyme and chemical inhibition analysis in HLMs, we found that berberine, coptisine, and palmatine were metabolized by CYP2D6, CYP3A4, and CYP1A2. CYP2D6 was the predominant enzyme involved in the metabolism of berberine (consistent with Guo’s finding [7]) and coptisine, while CYP1A2 was the primary contributor toward palmatine metabolism.

The enzymatic kinetic studies revealed that the \(\text{CL}_{\text{int}}\) values for the formation of two berberine metabolites in HLMs were approximately 2 to 3-fold higher than those of coptisine and palmatine.

In this study, we found that there were different degrees of metabolic interaction between the four components. Berberine showed a weak inhibitory effect on the production of coptisine metabolite with an IC₅₀ value of 115 \(\mu\)M. Palmatine and jatrorrhizine had little inhibitory effect on the formation of coptisine metabolite. Furthermore, berberine, coptisine, and jatrorrhizine showed no inhibitory effect on the generation of palmatine metabolite (IC₅₀ > 200 \(\mu\)M). However, coptisine showed the strongest inhibition toward berberine metabolism. As described above, berberine was metabolized mainly via CYP2D6 in HLMs and produced two major metabolites (B1 and B2), while coptisine had a strong inhibitory effect on CYP2D6 with IC₅₀ values of 4.4 \(\mu\)M [10]. Coptisine decreased the amount of B1 and B2 produced with IC₅₀ values of 6.5 and 8.3 \(\mu\)M in HLMs, respectively. It indicated that the production of B1 and B2 was decreased in liver due to CYP2D6 being inhibited by coptisine.

The alkaloids in Coptis chinensis are poorly absorbed when taken orally, resulting in low oral bioavailability [12, 15, 18, 19]; the plasmas concentration of coptisine cannot reach 6.5 \(\mu\)M. However, this concentration can be reached in liver because of tissue distribution [11].

In conclusion, coexisting constituents (coptisine) in Coptis chinensis inhibited the metabolism of berberine in liver and might increase its bioavailability. The present finding provides novel insight into the understanding of the metabolism-based synergistic mechanism of the coexisting constituents in herb.

Conflict of Interests

The authors have declared that there is no conflict of interests.

Authors’ Contribution

Songcan Liu and Xinfeng Zhang equally contributed to this work.

Acknowledgments

The first author sincerely thanks the native English-speaking experts of BioMed Proofreading for their support of the paper preparation. This work was supported by NSFC (Grant 81173118) and grants for building research technology and development of innovative drug (Grant 2012ZX09303009-001), the construction program for innovative research team in Shanghai institutions of higher education, and Shanghai key lab of traditional clinical medicine (Grant C10dZ2220200).

References

[1] Chinese Pharmacopoeia Commission, Pharmacopoeia of the People’s Republic of China, vol. 1, Chinese Medicinal Science and Technology Press, Beijing, China, 2010, (Chinese).
[2] J. Sun, J.-S. Ma, J. Jin et al., “Qualitative and quantitative determination of the main components of Huanglianjieju decoction by HPLC-UV/MS,” Yaoxue Xuebao, vol. 41, no. 4, pp. 380–384, 2006.
[3] U. K. Choi, M. H. Kim, and N. H. Lee, “Optimization of antibacterial activity by gold-thread (Coptidis Rhizoma Franch) against Streptococcus mutans using evolutionary operation-factorial design technique,” Journal of Microbiology and Biotechnology, vol. 17, no. 11, pp. 1880–1884, 2007.
[4] Y. F. Zhang, X. Y. Li, D. J. Zou et al., “Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 7, pp. 2559–2565, 2008.
[5] L. Yuan, D. Tu, X. Ye, and J. Wu, “Hypoglycemic and hypcholesterolemic effects of Coptis chinensis franch inflorescence,” Plant Foods for Human Nutrition, vol. 61, no. 3, pp. 139–144, 2006.
[6] N. Pinto and M. E. Dolan, “Clinically relevant genetic variations in drug metabolizing enzymes,” Current Drug Metabolism, vol. 12, no. 5, pp. 487–497, 2011.
[7] Y. Guo, F. Li, X. Ma, X. Cheng, H. Zhou, and C. D. Klaassen, “CYP2D plays a major role in berberine metabolism in liver of mice and humans,” Xenobiotica, vol. 41, no. 11, pp. 996–1005, 2011.
[8] Y. Zhang, W. Wu, F. Han, and Y. Chen, “LC/MS/MS for identification of in vivo and in vitro metabolites of jatrorrhizine,” Biomedical Chromatography, vol. 22, no. 12, pp. 1360–1367, 2008.
[9] R. Shi, H. Zhou, B. Ma et al., “Pharmacokinetics and metabolism of jatrorrhizine, a gastric prokinetic drug candidate,” *Biopharmaceutics & Drug Disposition*, vol. 33, no. 3, pp. 135–145, 2012.

[10] Y.-L. Han, H.-L. Yu, D. Li et al., “*In vitro* inhibition of *huanglian* [*Rhizoma coptidis* (L.)] and its six active alkaloids on six cytochrome P450 isoforms in human liver microsomes,” *Phytotherapy Research*, vol. 25, no. 11, pp. 1660–1665, 2011.

[11] Y.-T. Liu, H.-P. Hao, H.-G. Xie et al., “Extensive intestinal first-pass elimination and predominant hepatic distribution of berberine explain its low plasma levels in rats,” *Drug Metabolism and Disposition*, vol. 38, no. 10, pp. 1779–1784, 2010.

[12] W. Hua, L. Ding, Y. Chen, B. Gong, J. He, and G. Xu, “Determination of berberine in human plasma by liquid chromatography-electrospray ionization-mass spectrometry,” *Journal of Pharmaceutical and Biomedical Analysis*, vol. 44, no. 4, pp. 931–937, 2007.

[13] FDA, “Guidance for industry: drug interaction studies-study design, data analysis, and implications for dosing and labeling,” http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072101.pdf.

[14] F. Qiu, R. Zhang, J. Sun et al., “Inhibitory effects of seven components of danshen extract on catalytic activity of cytochrome P450 enzyme in human liver microsomes,” *Drug Metabolism and Disposition*, vol. 36, no. 7, pp. 1308–1314, 2008.

[15] F. Zuo, N. Nakamura, T. Akao, and M. Hattori, “Pharmacokinetics of berberine and its main metabolites in conventional and pseudo germ-free rats determined by liquid chromatography/ion trap mass spectrometry,” *Drug Metabolism & Disposition*, vol. 34, no. 12, pp. 2064–2072, 2006.

[16] Y. T. Liu, H. P. Hao, H. G. Xie, H. Lv, C. X. Liu, and G. J. Wang, “Oxidative demethylation and subsequent glucuronidation are the major metabolic pathways of berberine in rats,” *Journal of Pharmaceutical Sciences*, vol. 98, no. 11, pp. 4391–4401, 2009.

[17] M. M. Zhu, F. M. Han, H. X. Chen, Z. H. Peng, and Y. Chen, “Identification of palmatine and its metabolites in rat urine by liquid chromatography/tandem mass spectrometry,” *Rapid Communications in Mass Spectrometry*, vol. 21, no. 13, pp. 2019–2022, 2007.

[18] M.-P. Shen, Q. Sun, and H. Wang, “Studies on the intravenous pharmacokinetics and oral absorption of berberine HCl in beagle dogs,” *Chinese Pharmacological Bulletin*, vol. 9, no. 1, pp. 64–67, 1993.

[19] C. Yu, H. Zhang, J. Pan et al., “Determination and preliminary studies of metabolism of berberine in human urine after oral administration,” *The Chinese Journal of Clinical Pharmacology*, vol. 16, pp. 36–39, 2000.